A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis

American Journal of Gastroenterology

Volumn 92, Issue 10, 1997, Pages 1867-1871

  Safdi, Michael ^a   DeMicco, Michael ^b   Sninsky, Charles ^b   Banks, Peter ^b   Wruble, Lawrence ^b   Deren, Julius ^b   Koval, George ^b   Nichols, Trent ^b   Targan, Stephan ^b   Fleishman, Candis ^b   Wiita, Brinda ^b  

^a Greater Cincinnati Gastroenterology Associates   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENEMA; MESALAZINE; PLACEBO;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG EFFICACY; FECES ANALYSIS; FEMALE; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTAL DRUG ADMINISTRATION; RECTUM HEMORRHAGE; SUSPENSION; TABLET; THORAX PAIN; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; ENEMA; FEMALE; HUMANS; MALE; MESALAMINE; TABLETS; TREATMENT OUTCOME;

EID: 0030827118     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Meyers S. Ulcerative colitis. In: Rakel RE, ed. Conn's current therapy. Philadelphia: WB Saunders, 1987:429-33.
2. Farmer RG. Ulcerative colitis and proctitis. In: Bayless TM, ed. Current therapy in gastroenterology and liver disease. Oklahoma City: BC Decker, 1984:303-4.
3. Cello JP, Schneiderman DJ. Ulcerative colitis. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease. Philadelphia: WB Saunders, 1989:1435-76.
4. Taffett SF, Das KM. Sulfasalazine: Adverse effects and desensitization. Dig Dis Sci 1983;28:833.
5. Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol Clin North Am 1992;21:643-58.
6. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5.
7. Friedman LS, Richter JM, Kirkham SE, et al. 5-Aminosalicyclic acid enemas in refractory distal ulcerative colitis: A randomized, controlled trial. Am J Gastroenterol 1986;81:412-8.
8. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8.
9. Campieri M, Gionchetti P, Belluzzi A, et al. Efficacy of 5-aminosalicyclic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig Dis Sci 1987;32(suppl):67S-70S.
10. Hanauer SB, Kane SV, Guernsey B, et al. Randomized clinical trial of mesalazine (5-ASA) enemas in distal ulcerative colitis: A dose-ranging, placebo-controlled study. Gastroenterology 1989;96:A195.
11. Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicyclic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991;32:929-31.
12. Pullan RD, Ganesh S, Mani V, et al. Comparison of bismuth citrate and 5-aminosalicyclic acid enemas in distal ulcerative colitis: A controlled trial. Gut 1993;34:676-9.
13. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: A meta-analysis. Aliment Pharmacol Ther 1995;9: 293-300.
14. Biddle W, Greenberger NJ, Swan JT, et al. 5-Aminosalicyclic acid enemas: Effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988;95:1075-9.
15. Guarino J, Ghatzinoff M, Berk T, et al. 5-Aminosalicyclic acid enemas in refractory distal ulcerative colitis: Long-term results. Am J Gastroenterol 1987;82:732-7.
16. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: A multicenter study. Ann Intern Med 1991;115:350-5.
17. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993;118:540-9.
18. Rachmilewitz D. Coated mesalazine (5-aminosalicyclic acid) versus sulfasalazine in the treatment of active ulcerative colitis: A randomized trial. BMJ 1989;298:82-6.
19. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicyclic acid (mesalazine) and sulfasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988;29:669-74.
20. Dew MJ, Harries AD, Evans N, et al. Maintenance of remission in ulcerative colitis with 5-aminosalicyclic acid in high doses by mouth. BMJ 1983;287:23-4.
21. Riley SA, Mani V, Goodman MJ. Comparison of delayed-release 5-aminosalicyclic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94:1383-9.
22. DeVos M, Verdievel H, Schoojans R, et al. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992;22:1338-42.
23. Schoonjans R, DeVos M, Schelfout A-M, et al. Distribution and concentrations of 5-aminosalicylic acid in rectosigmoid biopsy specimens after rectal administration. Dis Colon Rectum 1996;39: 788-93.